Key Insights

Highlights

Success Rate

98% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.4%

1 terminated out of 70 trials

Success Rate

97.7%

+11.2% vs benchmark

Late-Stage Pipeline

6%

4 trials in Phase 3/4

Results Transparency

24%

10 of 42 completed with results

Key Signals

10 with results98% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (6)
Early P 1 (2)
P 1 (17)
P 2 (17)
P 3 (2)
P 4 (2)

Trial Status

Completed42
Recruiting15
Active Not Recruiting5
Withdrawn3
Enrolling By Invitation2
Not Yet Recruiting1

Trial Success Rate

97.7%

Benchmark: 86.5%

Based on 42 completed trials

Clinical Trials (70)

Showing 20 of 20 trials
NCT07013292RecruitingPrimary

Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia

NCT06623890RecruitingPrimary

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

NCT06865482RecruitingPrimary

Clinical Course Of Disease In Participants With FA-CM

NCT04577352Phase 2CompletedPrimary

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

NCT07508631RecruitingPrimary

Friedreich Ataxia Nerve Ultrasund

NCT05943002RecruitingPrimary

Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia

NCT05302271Phase 1RecruitingPrimary

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

NCT06447025Phase 2RecruitingPrimary

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

NCT06953583Phase 3RecruitingPrimary

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)

NCT06681766Phase 1TerminatedPrimary

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

NCT02255435Phase 2CompletedPrimary

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

NCT06496451CompletedPrimary

Measurement of Frataxin mRNA in Biofluids

NCT06054893Phase 1RecruitingPrimary

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

NCT05445323Phase 1Active Not RecruitingPrimary

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

NCT05168774Phase 1CompletedPrimary

FRDA Investigator Initiated Study (IIS) With Elamipretide

NCT06483802Phase 1WithdrawnPrimary

A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia

NCT06539598Not ApplicableCompletedPrimary

Respiratory Training in Friedreich's Ataxia

NCT05515536Phase 3Active Not RecruitingPrimary

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

NCT06605612Enrolling By Invitation

Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders

NCT05485987Phase 2CompletedPrimary

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Scroll to load more

Research Network

Activity Timeline